Table 5.
5- and 10-year breast cancer–specific survival (BCSS).
Subtype | 5-year BCSS | 10-year BCSS |
---|---|---|
Luminal A-like | 99.6% | 97.9% |
HER2 overexpression | 92.4% | 88.6% |
Luminal B-like (HER2 negative) | 95.7% | 86.3% |
TNBC | 85.6% | 83.9% |
Luminal B-like (HER2 positive) | 89.5% | 80.6% |
Whole cohort | 95.8% | 91.4% |